Age-Related Macular Degeneration Epidemiology Analysis and Forecast, 2021-2031

Pages: 44 Published: June 27, 2022 Report Code: GDHCER295-22

In 2021, there were 79,030,963 total prevalent cases of Age-Related Macular Degeneration (AMD). The cases are expected to rise at an annual growth rate (AGR) of more than 1% during the forecast period. AMD epidemiology market research report also includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of AMD, each segmented into early AMD and late AMD and broken down by sex and age (50–59 years, 60–69 years, 70–79 years, and 80 years and older). The total and diagnosed prevalent cases of late AMD are further segmented into late dry AMD and late wet AMD. The report also includes the total prevalent cases and diagnosed prevalent cases of geographic atrophy (GA) in these markets.

Age-related macular degeneration (AMD) is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly. AMD is classified into three stages: early AMD, intermediate AMD, and late AMD. Late AMD is the advanced stage of AMD, which is characterized by the presence of late dry AMD or late wet AMD. According to a meta-analysis study, the pooled prevalence of any AMD was reported to be a share among adults ages 45–85 years. In addition to the high prevalence of the condition, AMD is also associated with severe disability and has a major impact on the quality of life and emotional well-being.

Age-Related Macular Degeneration Epidemiology Analysis and Forecast

For more insights, download a free report sample

What are the key segments in the AMD market?

The key segments in the AMD market are Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and GA. In 2021, the US accounted for a significant share of the total prevalent cases of early AMD in the 7MM. However, Spain is expected to have the highest AGR in the forecast period. Similarly for Late AMD, again the US has the highest number of prevalent cases among the 7MM. In case of Late Dry AMD, the UK is expected to have the highest AGR during the forecast period. In case of Late Wet AMD, the US has a significant percentage of cases, and the UK is expected to have the highest AGR. Similarly in case of GA, the UK is expected to have the highest AGR during the forecast period.

Market report overview

Total no. of cases 79,030,963
AGR% (2021-2031) >1%
Key segments Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and GA

Scope

  • This report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report also includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of AMD, each segmented into early AMD and late AMD and broken down by sex and age (50–59 years, 60–69 years, 70–79 years, and 80 years and older). The total and diagnosed prevalent cases of late AMD are further segmented into late dry AMD and late wet AMD. The report also includes the total prevalent cases and diagnosed prevalent cases of geographic atrophy (GA) in these markets. The forecast is supported by robust, country-specific data that was obtained from various authentic sources such as research articles published in peer-reviewed journals. In addition, in the case of data scarcity, GlobalData epidemiologists used primary market research (PMR) data wherever necessary.
  • The AMD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

  • The AMD Epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global AMD market.
  • Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for AMD therapeutics in each of the markets covered.
  • Understand magnitude of AMD by early AMD and late AMD. Late AMD are further segmented into late dry AMD and late wet AMD.

Table of Contents

| About GlobalData

1 Age-Related Macular Degeneration: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 7MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Forecast Assumptions and Methods: Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD

2.4.4 Forecast Assumptions and Methods: Total Prevalent Cases of GA

2.4.5 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and GA

2.5 Epidemiological Forecast for AMD (2021–31)

2.5.1 Total Prevalent Cases of AMD

2.5.2 Age-Specific Total Prevalent Cases of AMD

2.5.3 Sex-Specific Total Prevalent Cases of AMD

2.5.4 Total Prevalent Cases of Early AMD

2.5.5 Total Prevalent Cases of Late AMD

2.5.6 Total Prevalent Cases of Late Dry AMD

2.5.7 Total Prevalent Cases of Late Wet AMD

2.5.8 Total Prevalent Cases of GA

2.5.9 Diagnosed Prevalent Cases of AMD

2.5.10 Age-Specific Diagnosed Prevalent Cases of AMD

2.5.11 Sex-Specific Diagnosed Prevalent Cases of AMD

2.5.12 Diagnosed Prevalent Cases of Early AMD

2.5.13 Diagnosed Prevalent Cases of Late AMD

2.5.14 Diagnosed Prevalent Cases of Late Dry AMD

2.5.15 Diagnosed Prevalent Cases of Late Wet AMD

2.5.16 Diagnosed Prevalent Cases of GA

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 Primary Research – Prescriber Survey

3.3 About the Authors

3.3.1 Epidemiologist

3.3.2 Reviewers

3.3.3 Global Director of Therapy Analysis and Epidemiology

3.3.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: Summary of Changes to Data Types and Countries

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbid Conditions Associated with AMD

Table 4: High-Prescribing Physicians (KOL and non-KOLs) Surveyed, By Country

List of Figures

Figure 1: 7MM, Total Prevalent Cases of AMD, Both Sexes, N, Ages ≥50 Years, 2021 and 2031

Figure 2: 7MM, Diagnosed Prevalent Cases of AMD, Both Sexes, N, Ages ≥50 Years, 2021 and 2031

Figure 3: 7MM, Total Prevalence of AMD, Men and Women, Ages ≥50 Years, %, 2021

Figure 4: 7MM, Diagnosed Prevalence of AMD, Men and Women, Ages ≥50 Years, 2021

Figure 5: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD

Figure 6: 7MM, Sources Used to Forecast the Total Prevalent Cases of GA and Diagnosed Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD

Figure 7: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 8: 7MM, Total Prevalent Cases of AMD by Age, Both Sexes, N, 2021

Figure 9: 7MM, Total Prevalent Cases of AMD, by Sex, Ages ≥50 Years, N, 2021

Figure 10: 7MM, Total Prevalent Cases of Early AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 11: 7MM, Total Prevalent Cases of Late AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 12: 7MM, Total Prevalent Cases of Late Dry AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 13: 7MM, Total Prevalent Cases of Late Wet AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 14: 7MM, Total Prevalent Cases of GA, Both Sexes, Ages ≥50 Years, N, 2021

Figure 15: 7MM, Diagnosed Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 16: 7MM, Diagnosed Prevalent Cases of AMD by Age, Both Sexes, N, 2021

Figure 17: 7MM, Diagnosed Prevalent Cases of AMD, by Sex, Ages ≥50 Years, N, 2021

Figure 18: 7MM, Diagnosed Prevalent Cases of Early AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 19: 7MM, Diagnosed Prevalent Cases of Late AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 20: 7MM, Diagnosed Prevalent Cases of Late Dry AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 21: 7MM, Diagnosed Prevalent Cases of Late Wet AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 22: 7MM, Diagnosed Prevalent Cases of GA, Both Sexes, Ages ≥50 Years, N, 2021

Frequently Asked Questions

Request a Free Sample
$3995

Can be used by individual purchaser only

$11985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.